NIH R01 · 2025
The impact of sex and cell death on checkpoint inhibitor hepatotoxicity
Project Summary Immune checkpoints have evolved to control self-reactivity, providing a break on the immune system. Cancer cells evade the immune system by overexpressing these checkpoints. Immune Checkpoint Inhibitors (ICI) block these evasion tactics and enhance anti-tumor responses, promoting cytotoxic T cell (CTL) survival, restoring tumor surveillance, and clearing malignant cells. These include monoclonal antibodies against two major immune checkpoints (although antibodies against other targets are in development): 1) The cytotoxic T-lymphocyte- associated protein 4 (CTLA-4) and 2) Programmed death-1 (PD-1) and PD-ligand 1 (PD-L1). Although immunotherapy is extremely effective,…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.